Cher ML - Search Results

1

Determinants of active surveillance uptake in a diverse population-based cohort of men with low-risk prostate cancer: The Treatment Options in Prostate Cancer Study (TOPCS).

Xu J, Bock CH, Janisse J, Woo J, Cher ML, Ginsburg K, Yacoub R, Goodman M. Xu J, et al. Among authors: cher ml. Cancer. 2024 May 15;130(10):1797-1806. doi: 10.1002/cncr.35190. Epub 2024 Jan 22. Cancer. 2024. PMID: 38247317

2

Angiogenic and antiangiogenic balance regulates concomitant antitumoral resistance.

Scharovsky OG, Binda MM, Rozados VR, Bhagat S, Cher ML, Bonfil RD. Scharovsky OG, et al. Among authors: cher ml. Clin Exp Metastasis. 2004;21(2):177-83. doi: 10.1023/b:clin.0000024762.32172.13. Clin Exp Metastasis. 2004. PMID: 15168735

3

Transitional cell carcinoma of the ureteral stump 23 years after radical nephrectomy for adenocarcinoma.

Cher ML, Milchgrub S, Sagalowsky AI. Cher ML, et al. J Urol. 1993 Jan;149(1):106-8. doi: 10.1016/s0022-5347(17)36013-5. J Urol. 1993. PMID: 8417186

4

Allelic loss at 16q23.2 is associated with good prognosis in high grade prostate cancer.

Fromont G, Valeri A, Cher M, Pontes JE, Vallancien G, Validire P, Latil A, Cussenot O. Fromont G, et al. Prostate. 2005 Dec 1;65(4):341-6. doi: 10.1002/pros.20304. Prostate. 2005. PMID: 16015610

5

Screening for prostate cancer.

Cher ML, Carroll PR. Cher ML, et al. West J Med. 1994 Mar;160(3):250. West J Med. 1994. PMID: 7514824 Free PMC article. No abstract available.

6

Identification of genetic alterations associated with the process of human experimental colon cancer liver metastasis in the nude mouse.

Yeatman TJ, Cher ML, Mao W, Wloch M, Tedesco T. Yeatman TJ, et al. Among authors: cher ml. Clin Exp Metastasis. 1996 May;14(3):246-52. doi: 10.1007/BF00053898. Clin Exp Metastasis. 1996. PMID: 8674279

7

Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases.

Nemeth JA, Cher ML, Zhou Z, Mullins C, Bhagat S, Trikha M. Nemeth JA, et al. Among authors: cher ml. Clin Exp Metastasis. 2003;20(5):413-20. doi: 10.1023/a:1025461507027. Clin Exp Metastasis. 2003. PMID: 14524530

8

Cellular proliferative fraction of metastatic lymph nodes predicts survival in stage D1 (TxN+M0) prostate cancer.

Cher ML, Stephenson RA, James BC, Carroll PR. Cher ML, et al. J Urol. 1996 May;155(5):1674-7. J Urol. 1996. PMID: 8627851

9

Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression.

Cher ML, Chew K, Rosenau W, Carroll PR. Cher ML, et al. Prostate. 1995 Feb;26(2):87-93. doi: 10.1002/pros.2990260205. Prostate. 1995. PMID: 7855002

10

Bone-induced c-kit expression in prostate cancer: a driver of intraosseous tumor growth.

Mainetti LE, Zhe X, Diedrich J, Saliganan AD, Cho WJ, Cher ML, Heath E, Fridman R, Kim HR, Bonfil RD. Mainetti LE, et al. Among authors: cher ml. Int J Cancer. 2015 Jan 1;136(1):11-20. doi: 10.1002/ijc.28948. Epub 2014 May 20. Int J Cancer. 2015. PMID: 24798488 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

153 results

Search Page

Filters